Shouyao Holdings Beijing Co., Ltd. (688197)

Overview

Shouyao Holdings (Beijing) Co., LTD., established in 2016 and headquartered in Beijing, China, operates in the pharmaceutical industry, focusing on the research, development, and production of drugs. The company is dedicated to addressing a wide range of medical conditions, with a particular emphasis on various forms of cancer and other diseases such as diabetes. Through its commitment to innovation and excellence, Shouyao Holdings has positioned itself as a key player in China’s pharmaceutical sector, contributing significantly to the healthcare landscape.

Products and Services

• Non-Small Cell Lung Cancer Treatments

  Offering innovative drugs targeted at treating non-small cell lung cancer, aiming to improve patient survival rates and quality of life.

• Lymphoma Medications

  Developing treatments for lymphoma that target the disease with precision, potentially reducing side effects and enhancing efficacy.

• Hepatocellular Carcinoma Solutions

  Providing therapies for hepatocellular carcinoma, focused on halting disease progression and improving liver function in patients.

• Pancreatic Cancer Drugs

  Researching and producing drugs designed to combat pancreatic cancer, striving to extend patient life expectancy and manage symptoms.

• Breast Cancer Treatments

  Creating medications for breast cancer that are tailored to the genetic makeup of the tumor, offering personalized therapy options.

• Ovarian and Thyroid Cancer Therapies

  Offering targeted treatments for ovarian and thyroid cancers, focusing on molecular and immunological approaches to treatment.

• Leukemia Medications

  Delivering drugs specifically designed to fight leukemia by attacking cancer cells while sparing healthy cells, thus minimizing side effects.

• Other Disease Treatments

  Beyond oncology, Shouyao Holdings also addresses chronic conditions such as diabetes with innovative treatments aimed at enhancing patient lives.